<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351103</url>
  </required_header>
  <id_info>
    <org_study_id>CLGK974X2101</org_study_id>
    <secondary_id>2011-000495-33</secondary_id>
    <nct_id>NCT01351103</nct_id>
  </id_info>
  <brief_title>A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands</brief_title>
  <official_title>A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to find the recommended dose of LGK974 as a single agent&#xD;
      and in combination with PDR001 that can be safely given to adult patients with selected solid&#xD;
      malignancies that have progressed despite standard therapy or for which no effective standard&#xD;
      therapy exists&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label multicenter phase 1 dose escalation study will be the first to administer&#xD;
      LGK974 as a single agent or in combination with PDR001 in humans.&#xD;
&#xD;
      The study will comprise of 2 parts: a dose escalation of LGK974 as a single agent, followed&#xD;
      by a safety expansion in specific disease indications; and a dose escalation of LGK974 in&#xD;
      combination with PDR001, followed by a safety expansion in cutaneous melanoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2011</start_date>
  <completion_date type="Anticipated">November 23, 2023</completion_date>
  <primary_completion_date type="Actual">June 14, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 as a single agent or in combination with PDR001 in patients treated</measure>
    <time_frame>34 months</time_frame>
    <description>Determine the Maximum Tolerated Dose (MTD) or Recommended Dose for Expansion (RDE) of LGK974 as a single agent and in combination with PDR001 when administered orally to adult patients with malignancies dependent on Wnt ligands.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type and category of study drug related adverse events (AE)</measure>
    <time_frame>61 months</time_frame>
    <description>The incidence of treatment-emergent adverse events (new or worsening from baseline) will be summarized by primary system organ class, severity based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, type of AE, relationship to study drug by dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption and plasma concentrations of LGK974</measure>
    <time_frame>61 months</time_frame>
    <description>Evaluate pharmacokinetic (PK) parameters such as AUClast, AUCtau, Cmax, the apparent elimination T1/2 and Racc for LGK974 and its pharmacologically metabolite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD related to the Wnt pathway</measure>
    <time_frame>61 months</time_frame>
    <description>Assessing percent change from baseline to post-treatment of PD related to the Wnt pathway.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate of tumor</measure>
    <time_frame>61 months</time_frame>
    <description>Patients with an Overall Response Rate(ORR), complete response (CR) or partial response (PR) rate and duration of response (DOR) assessed by RECIST 1.1 for single agent LGK974 and by RECIST1.1 and irRC for LGK974+PDR001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorportion and plasma concentrations of PDR001</measure>
    <time_frame>61 months</time_frame>
    <description>Evaluate pharmacokinetic (PK) parameters such as AUClast, AUCtau, Cmax, the apparent elimination T1/2 and Racc for LGK974, its pharmacologically metabolite and PDR001.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>BRAF Mutant Colorectal Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Head and Neck Squamous Cell Cancer</condition>
  <condition>Cervical Squamous Cell Cancer</condition>
  <condition>Esophageal Squamous Cell Cancer</condition>
  <condition>Lung Squamous Cell Cancer</condition>
  <arm_group>
    <arm_group_label>LGK974</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LGK974</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGK974 in combination with PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LGK in combination with PDR001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGK974</intervention_name>
    <arm_group_label>LGK974</arm_group_label>
    <arm_group_label>LGK974 in combination with PDR001</arm_group_label>
    <other_name>WNT974</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <arm_group_label>LGK974 in combination with PDR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosis of locally advanced or metastatic cancer that has progressed despite standard&#xD;
        therapy or for which no effective standard therapy exists and histological confirmation of&#xD;
        one of the following diseases indicated below:&#xD;
&#xD;
        Single Agent Dose escalation part:documented B-RAF mutant colorectal cancer or pancreatic&#xD;
        adenocarcinoma. In addition, tumors of any histological origin with documented genetic&#xD;
        alterations upstream in the Wnt signaling pathway are eligible with prior agreement with&#xD;
        Novartis.&#xD;
&#xD;
        Single Agent Dose expansion part: documented B-RAF mutant colorectal cancer with documented&#xD;
        RNF43 mutation and/or RSPO fusion or pancreatic adenocarcinoma with documented RNF43&#xD;
        mutation. In addition, patients with tumors of any histological origin with documented&#xD;
        genetic alterations upstream in the Wnt signaling pathway (e.g. RNF43 or RSPO fusion) are&#xD;
        eligible with prior agreement with Novartis&#xD;
&#xD;
        LGK974 with PDR001: Dose escalation: patients with the following cancers that were&#xD;
        previously treated with anti-PD-1 therapy and whose best response on that therapy was&#xD;
        progressive disease (i.e. primary refractory): melanoma, lung SCC, HNSCC. Patients with&#xD;
        esophageal SCC, cervical SCC or TNBC who are either na√Øve or primary refractory to prior&#xD;
        anti-PD-1 therapy.&#xD;
&#xD;
        LGK974 with PDR001: Dose expansion: patients with:&#xD;
&#xD;
          -  cutaneous melanoma that was primary refractory to prior anti-PD-1 therapy, defined as&#xD;
             a best response of progressive disease or stable disease for &lt;= 4 months, or disease&#xD;
             recurrence with the first 6 months of adjuvant therapy. Patients with BRAF V600-mutant&#xD;
             melanoma must have also received and been failed by prior systemic therapy with BRAF&#xD;
             V600 inhibitor, with or without a MEK inhibitor.&#xD;
&#xD;
          -  Cutaneous melanoma with acquired resistance to prior anti-PD-1 therapy, defined as&#xD;
             progressive disease following response (PR or CR) or following stable disease for &gt; 4&#xD;
             months. Patients with BRAF V600-mutant melanoma must have also received and been&#xD;
             failed by prior systemic therapy with a BRAF V600 inhibitor, with or without a MEK&#xD;
             inhibitor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired cardiac function&#xD;
&#xD;
          -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of LGK974 (e.g., ulcerative diseases, uncontrolled&#xD;
             nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)&#xD;
&#xD;
          -  Brain metastases that have not been adequately treated&#xD;
&#xD;
          -  Malignant disease other than that being treated in this study&#xD;
&#xD;
          -  Laboratory abnormalities as specified in the protocol&#xD;
&#xD;
          -  Osteoporosis, osteopenia&#xD;
&#xD;
          -  Bone fractures within the past year&#xD;
&#xD;
          -  Pathologic bone fracture&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease or severe hypersensitivity reactions to&#xD;
             other monoclonal antibodies&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth O Laco</last_name>
      <phone>310-794-0738</phone>
      <email>EOLaco@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Antoni Ribas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Raynor</last_name>
      <phone>410-502-2377</phone>
      <email>craynor1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Forde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute SC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute SC-7</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marios Giannakis, M.D., Ph.D.</last_name>
      <phone>617-632-6805</phone>
      <email>Marios_Giannakis@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Marios Giannakis, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center Onc Dept.</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0944</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute Wayne St</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swathi Balaji</last_name>
      <phone>212-304-5548</phone>
      <email>zs2423@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Carvajal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center MD Anderson 2</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stepanek M. Vanda</last_name>
      <phone>713-792-2921</phone>
      <email>vstepane@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Filip P. Janku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LGK974</keyword>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>BRAF mutant colorectal cancer</keyword>
  <keyword>RNF43 mutation</keyword>
  <keyword>RSPO fusion</keyword>
  <keyword>melanoma</keyword>
  <keyword>triple negative breast cancer</keyword>
  <keyword>PDR001</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>head and neck scc</keyword>
  <keyword>cervical scc</keyword>
  <keyword>esophageal scc</keyword>
  <keyword>lung scc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
    <mesh_term>LGK974</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

